---
title: "Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285249366.md"
description: "Krystal Biotech (KRYS) reported strong Q1 earnings, with earnings of $1.83 per share and sales of $116.357 million, both exceeding analyst estimates. Despite a 1% drop in shares to $284.01, analysts have raised their price targets, with Evercore ISI maintaining an Outperform rating and increasing the target from $295 to $300, while Citigroup raised its Buy target from $371 to $378. CEO Krish S. Krishnan highlighted the company's momentum and potential for future growth with ongoing global expansion and pipeline developments."
datetime: "2026-05-05T18:19:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285249366.md)
  - [en](https://longbridge.com/en/news/285249366.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285249366.md)
---

# Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

**Krystal Biotech Inc** (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.

The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.

“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”

Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.

These analysts made changes to their price targets on Krystal Biotech following earnings announcement.

-   Evercore ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.
-   Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.

**Considering buying KRYS stock? Here’s what analysts think:**

_Photo via Shutterstock_

### Related Stocks

- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)